The estimated Net Worth of Paula Ragan is at least $4.08 Milione dollars as of 11 March 2024. Paula Ragan owns over 49,678 units of X4 Pharmaceuticals stock worth over $527,897 and over the last 5 years he sold XFOR stock worth over $1,057,302. In addition, he makes $2,497,790 as President, Chief Executive Officer, Corporate Secretary e Director at X4 Pharmaceuticals.
Sign up
Paula Ragan XFOR stock SEC Form 4 insiders trading
Paula has made over 33 trades of the X4 Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 49,678 units of XFOR stock worth $43,717 on 11 March 2024.
The largest trade he's ever made was selling 239,437 units of X4 Pharmaceuticals stock on 1 November 2023 worth over $181,972. On average, Paula trades about 13,072 units every 35 days since 2019. As of 11 March 2024 he still owns at least 765,068 units of X4 Pharmaceuticals stock.
You can see the complete history of Paula Ragan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paula Ragan biography
Dr. Paula Ragan Ph.D. serves as President, Chief Executive Officer, Corporate Secretary, Director of the Company. Dr. Ragan has been the President, Chief Executive Officer and a member of the board of directors of X4 since July 2014. She has more than 18 years of experience building companies in the biotechnology industry. From August 2012 to September 2014, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc., a private biopharmaceutical company, where she led the company’s business development activities. Prior to that, from January 2007 to August 2012, Dr. Ragan held leadership roles in corporate development and operations at Genzyme Corporation, a Sanofi company, where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her B.S. from Tufts University and her Ph.D. from Massachusetts Institute of Technology and completed post-doctoral studies at Harvard Medical School. Ragan’s perspective and experience as our President and Chief Executive Officer, which provides the board with historic knowledge, operational expertise and continuity, provides her with the qualifications and skills to serve on our board of directors.
What is the salary of Paula Ragan?
As the President, Chief Executive Officer, Corporate Secretary e Director of X4 Pharmaceuticals, the total compensation of Paula Ragan at X4 Pharmaceuticals is $2,497,790. There are no executives at X4 Pharmaceuticals getting paid more.
How old is Paula Ragan?
Paula Ragan is 50, he's been the President, Chief Executive Officer, Corporate Secretary e Director of X4 Pharmaceuticals since 2019. There are 9 older and 4 younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals, Inc. is Dr. Robert David Arbeit, 73, who is the Sr. VP of Clinical Devel. and Translational Research.
What's Paula Ragan's mailing address?
Paula's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134.
Insiders trading at X4 Pharmaceuticals
Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa e Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.
What does X4 Pharmaceuticals do?
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
What does X4 Pharmaceuticals's logo look like?
Complete history of Paula Ragan stock trades at X4 Pharmaceuticals
X4 Pharmaceuticals executives and stock owners
X4 Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Paula Ragan,
President, Chief Executive Officer, Corporate Secretary, Director -
Adam Mostafa,
Chief Financial Officer, Treasurer -
Dr. Paula Ragan Ph.D.,
Founder, CEO, Pres, Sec. & Director -
Derek M. Meisner Esq., J.D.,
Chief Legal Officer & Corp. Sec. -
Adam S. Mostafa,
CFO, Treasurer & Assistant Sec. -
Michael Wyzga,
Independent Chairman of the Board -
Gary Bridger,
Independent Director -
Murray Stewart,
Independent Director -
David McGirr,
Independent Director -
William Aliski,
Independent Director -
Rene Russo,
Director -
Candice Ellis,
Director, Corporate Communications & Investor Relations -
Alison Lawton,
Director -
Derek Meisner,
General Counsel -
Arthur Taveras,
Chief Scientific Officer -
Dr. Diego Cadavid M.D.,
Chief Medical Officer -
Carrie Melvin M.B.A.,
Sr. VP of Devel. Operations -
Dr. Robert David Arbeit,
Sr. VP of Clinical Devel. and Translational Research -
Ronny Mosston M.B.A.,
Sr. VP of HR -
Dr. Mary DiBiase Ph.D.,
Chief Operating Officer -
Keith Woods,
Director -
Craecker Francoise De,
Director -
Christophe Arbet Engels,
Chief Medical Officer -
Renato Skerlj,
Chief Scientific Officer -
Lynne E Kelley,
Chief Medical Officer -
Diego Cadavid,
Chief Medical Officer -
Mary Di Biase,
Chief Operating Officer